Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roluperidone and Olanzapine Co-Administration in Schizophrenia
NCT06107803Phase 1Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of roluperidone in schizophrenia, sponsored by Minerva Neurosciences, Inc. Primary endpoints: Change From Baseline in Abnormal Involuntary Movement Scale Component Movement at Day 17, Change From Baseline in Barnes Akathisia Rating Scale at Day 17 and 1 more. Started Oct 2023; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06107803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107803.